TUESDAY, Sept. 29, 2015 (HealthDay News) -- Eudaimonic well-being is associated with lower tumor norepinephrine (NE) in women with epithelial ovarian cancer, according to a study published in the Oct. 1 issue of Cancer.

Lauren Z. Davis, from the University of Iowa in Iowa City, and colleagues assessed how two different aspects of well-being (eudaimonic and positive affect) and psychological distress were associated with tumor NE in 365 patients with ovarian cancer. High-performance liquid chromatography with electrochemical detection was used to measure tumor NE in frozen tissue samples.

The researchers found that eudaimonic well-being, positive affect, and psychological distress modeled as distinct, but correlated constructs. A good model fit was found for structural equation modeling analysis that included physical well-being, stage of disease, histology, psychological treatment history, beta-blocker use, and caffeine use as covariates. This model demonstrated that eudaimonic well-being was related to lower tumor NE (P = 0.045), while no effects were found for positive affect or psychological distress.

"Because adrenergic signaling is implicated in tumor progression, increasing eudaimonic well-being may improve both psychological and physiologic resilience in patients with ovarian cancer," the authors write.

Two authors disclosed financial ties to the medical device industry.

Full Text (subscription or payment may be required)

Physician's Briefing

Updated on May 31, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ